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Progressive neutrophil-mediated lung damage causes much of the morbidity and mortality in cystic fibrosis (CF).
Neutrophil chemoattractants implicated in CF include interleukin (IL-)8, tumour necrosis factor (TNFa) and
leukotriene (LT)B4, but growth-related protein a (GROa), a highly potent neutrophil chemokine, has not been
investigated. Atopic status has been considered to contribute to the marked heterogeneity of pulmonary disease in
CF. We hypothesized that GROa may be produced in biologically-significant amounts in the CF lung, and that
enhanced production of GROa, IL-8 or LTB4 may contribute to the poorer lung function seen in atopic CF
patients compared to non-atopic CF patients. GROa, IL-8 and LTB4 levels in the sputum of atopic and non-atopic
CF patients were assessed by immunoassays, and GROa and IL-8 levels were also assessed in the plasma of CF
patients and normal controls. As expected, there were high levels of IL-8 and LTB4 in most CF sputum samples,
and IL-8 levels were higher in CF plasma than in control plasma (P002). In contrast, GROa was undetectable
(55 pg ml71) in the sputum of 21 out of 25 CF patients, with low levels (range 144–825 pg ml71) in the remainder,
and median levels of GROa in CF plasma (33 pg ml71, n24) were not significantly dierent from controls
(34 pg ml71, n25). Lung function [forced expiratory volume in 1 sec (FEV1) and forced vital capacity (FVC)] was
significantly poorer in atopic CF compared to non-atopic CF patients (P5002), but sputum levels of GROa, IL-8
and LTB4 were not dierent between the subgroups. Our results suggest that unlike LTB4 and IL-8, GROa does
not contribute to neutrophilic inflammation in the CF lung, and other factors must determine the impaired lung
function observed in atopic CF patients. These results may have important implications in the development of
chemokine receptor antagonists as novel anti-inflammatory agents in CF.
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Unrestrained local inflammation contributes significantly
to progressive lung damage in cystic fibrosis (CF), mediated
primarily by toxic products of neutrophils, especially
oxygen free radicals and elastase. The mobilization of
neutrophils from the circulation into the lungs is a complex
series of events largely aected by adhesion molecule
interactions and the production of chemoattractant lipids
and cytokines, including leukotriene (LT)B4, tumour
necrosis factor (TNFa), interleukin (IL)-1, neutrophil-
activating peptide (ENA-78) and IL-8. LTB4 and IL-8
have been specifically implicated in airway inflammation in
the CF lung (1,2). Growth-related protein alpha (GROa) is
a chemokine of the a sub-family and is structurally relatedReceived 8 October 1998 and accepted in revised form 25 March
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0954-6111/00/020106+06 $35?00/0to IL-8, but with even more potent neutrophil chemoat-
tractant activity which is exerted via the IL-8 receptor (3).
Previously described as growth-related oncogene product a
and melanocyte growth-stimulating activity (MGSA),
GROa is released in response to IL-1, TNFa and other
pro-inflammatory stimuli acting on melanoma and other
malignant cells, and also from normal cells including
monocyte–macrophages, platelets and endothelial cells.
GROa is implicated in conditions characterized by chronic
neutrophilic inflammation, such as psoriasis and rheuma-
toid arthritis (4,5), and levels of GROa 3- to 7-fold higher
than those of IL-8 have been found in bronchoalveolar
lavage (BAL) fluid from patients with bacterial pneumonia,
adult respiratory distress syndrome and Pneumocystis
pneumonia (6). However, the role of GROa in CF has
never been explored. We hypothesized that GROa may be
important in perpetuating neutrophilic inflammation in the
CF lung.
The severity of lung disease varies enormously in patients
with CF, even between siblings and between non-related
patients with the same CFTR genotype. It is likely that# 2000 HARCOURT PUBLISHERS LTD
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heterogeneity, and many of these factors are unclear. While
neutrophilic inflammation usually occurs in response to
infection, high levels of inflammatory markers have also
been demonstrated in bronchoalveolar lavage fluid (BALF)
of CF infants for whom clinical and microbiological
evidence of associated infection is unconvincing (7,8). We
have previously described the adverse influence of positive
atopic status on lung function in CF, and its association
with increased production of bronchoconstrictor cysteinyl-
leukotrienes, compared to non-atopic CF patients (9,10,11).
We hypothesized that atopic CF patients may also over-
produce the neutrophil chemotaxin LTB4. Since LTB4 has
immunomodulatory actions in regulating cytokine expres-
sion by mononuclear cells (12,13) a putative overproduc-
tion of LTB4 may lead to enhanced neutrophil migration in
atopic CF patients compared to non-atopic CF patients not
only by direct chemotaxis, but also indirectly by inducing
expression of IL-8 and/or GROa from other cells.
We aimed therefore, firstly to determine whether GROa
is present in the sputum and plasma of CF patients at
biologically-significant levels, and secondly, to relate atopic
status to sputum levels of IL-8, GROa and LTB4, and to
impairment of lung function.
Methods
PATIENT RECRUITMENT AND SAMPLE
COLLECTION
Ethical approval was obtained from King’s Healthcare and
Great Ormond Street Hospital for Children, Research
Ethics Committees. Samples of sputum (n25) and plasma
(n24) were collected from CF patients recruited at these
regional paediatric clinics. The diagnosis of CF had been
confirmed by sweat sodium levels above 60 mmol l71 and/
or by the presence of two known CF gene mutations. The
atopic CF patients were defined by one or more positive
skin reactions ( 3 mm compared to control) to a panel of
eight common allergens (cat and dog hair, house dust mite,
house dust, mixed moulds, tree and grass pollens, mixed
feathers). Mean (+SD) ages of the atopic CF patients
(137+33 yr) and non-atopic CF patients (122+36 yr)
were not significantly dierent. Lung function was assessed
from spirometric measurements of forced expiratory
volume (FEV1) and forced vital capacity (FVC), expressed
as a percentage of those predicted for age, sex and height
(14). Lung function was used to detect dierences between
atopic and non-atopic CF patients and was also correlated
with sputum levels of LTB4, IL-8 and GROa. Subjects were
excluded by the use of corticosteroids, theophylline or non-
steroidal anti-inflammatory drugs within the preceding four
weeks. Control plasma was obtained from 25 healthy
children (933+31 yr) having routine blood sampling prior
to minor surgical procedures. Seven of the control subjects
had positive skin prick tests, and four other controls, with
negative skin tests, were considered to be atopic on the
basis of an elevated serum total IgE (with levels of 806, 863
and two 41000 IU/ml respectively).Where possible sputum was obtained from CF patients
when they were clinically stable. However four subjects
were only able to expectorate sputum whilst on IV
antibiotics for an exacerbation. Their sputum IL-8 and
LTB4 levels were no greater than the other patients and
they had undetectable GROa levels. The volume of sputum
available for analysis from the remainder of the subjects
was limited and tests for GROa and IL-8 were prioritized.
Sputum samples were collected onto ice and stored at
7208C. Initial mucolysis was achieved using an equal
volume of 100% N-acetylcysteine. Samples were then
liquefied by homogenization and debris removed by low-
speed centrifugation. The supernatant was divided into
separate aliquots for analysis of LTB4 and cytokines. Blood
anti-coagulated with EDTA was collected onto ice,
centrifuged within 30 min and the plasma stored at7208C.
HPLC/RADIOIMMUNOASSAY OF LTB4 IN
SPUTUM
Liquefied sputum samples from 14 of the 25 CF patients
(eight atopic, six non-atopic) were available for LTB4
analysis. Tritium-labelled LTB4 (4nCi; Amersham, U.K.)
was added to allow correction for losses of endogenous
LTB4 during purification. The sputum was treated with
four volumes of methanol at 48C for 30 min, and debris
removed by centrifugation at 1000g for 20 min. The
supernatant was evaporated to dryness and reconstituted
in distilled water. LTB4 was further purified using Sep-Pak
octadecylsilane cartridges (Millipore, Watforch, U.K.) and
high performance liquid chromatography (HPLC) with
reverse-phase C18 columns and a methanol/water mobile
phase as described previously (1). Radioimmunoassay
(RIA) for LTB4 was then performed as described (1) using
a highly specific rabbit polyclonal antibody (gift of Dr
A.W. Ford-Hutchinson, Merck-Frosst, Canada) with a
minimum detection limit of approximately 20 pg ml71.
ENZYME IMMUNOASSAYS OF IL-8 AND
GRO IN SPUTUM AND PLASMA
Interleukin-8 and GROa were measured in liquefied
sputum (n25) or plasma by specific and sensitive
Quantikine enzyme linked immunosorbent assays (ELISA)
(R&D Systems, Abingdon, U.K.) in accordance with the
manufacturer’s instructions. Samples were added to micro-
titre wells precoated with monoclonal antibody to the
human recombinant cytokine and incubated for 2 h at
room temperature. Wells were treated with a secondary
antibody conjugated to horseradish peroxidase and bound
cytokine visualized with tetramethylbenzidine chromogen
and hydrogen peroxide by spectrophotometry at 450 nm.
Assays were calibrated from a standard curve constructed
using recombinant human cytokine over the range 0–6000
pg ml71 for IL-8 and 0–1000 pg ml71 for GROa. Minimum
detection limits were consistent with those determined by
the kit manufacturer (5181 pg ml71 for IL-8 and 55 pg
ml71 for GROa).
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The normal range of GROa levels in sputum has not been
fully established, which precluded power calculations, but
the numbers of subjects in each group were based on
previous published CF studies showing significant dier-
ences in cytokine and leukotriene levels (1,2,9). LTB4, IL-8
and GROa levels were non-normally distributed and group
comparisons were performed by Mann–Whitney U-test for
non-parametric data. Results are described as median and
range. FEV1 and FVC were normally distributed and group
comparisons were performed by unpaired Student’s t-test.
These results are described as mean+SD. Analyses were
performed using the Minitab statistical package and
P  005 was considered significant.
Results
LUNG FUNCTION
FEV1 was significantly lower in atopic CF patients
(412+14.7% predicted, n12) than in non-atopic CF
patients (594+166%; n13, P0008). FVC was also
significantly lower in the atopic CF group (545+197%)
than in the non-atopic CF group (72+209%, P002).
The relatively poor lung function in both CF subgroups
may reflect their selection as reliable producers of sputum
samples.FIG. 1. Sputum levels of interleukin-8 (left), leukotriene B4 (cen
children with cystic fibrosis (CF). Median values are shown as ho
detectable (55 pg ml71) in 10 out of 12 atopic CF patients and
significant dierences between the atopic and non-atopic CF paSPUTUM IL-8, LTB4, AND GRO
CONCENTRATIONS
Enzyme immunoassay showed that IL-8 was present at
detectable levels (4181 pg ml71) in the sputum of nine out
of 12 atopic CF patients and in 12 out of 13 non-atopic CF
patients [Fig. 1(a)]. IL-8 concentrations were not signifi-
cantly dierent in the atopic CF group (404 pg ml71, range
5181–7836) compared to the non-atopic CF group (738
pg ml71, range 5181–9008; P018). Sputum also
contained high levels of LTB4, with concentrations in
atopic CF patients (723 pg ml71, range 301–1199, n8) not
significantly dierent from those in non-atopic CF patients
(1020 pg ml71, range 571–3298, n6; P03) [Fig. 1(b)]. In
contrast, GROa levels were undetectable (55 pg ml71) in
10 out of 12 atopic CF patients and in 11 out of 13 non-
atopic CF patients [Fig. 1(c)]. The remaining two patients
in each CF subgroup had low GROa levels ranging from
144 to 824 pg ml71. Levels of IL-8, LTB4 and GROa in CF
sputum showed no significant correlations with FEV1 or
FVC (r2 01, P 01).
PLASMA IL-8 AND GRO
CONCENTRATIONS
The CF group comprized 24 subjects as additional plasma
samples were obtained from two atopic patients who were
unable to produce sputum, and three of the non-atopictre) and GROa (right) in atopic (A) and non-atopic (NA)
rizontal bars. In contrast to IL-8 and LTB4, GROa was not
in 11 out of 13 non-atopic CF patients. There were no
tients in sputum levels of IL-8, LTB4 or GROa.
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provide a blood sample. The apparent division of control
subjects into two groups according to their plasma IL-8
level [Fig. 2(a)] is considered artificial and the undetectable
levels are likely to form a continuum. No normal subject
had any evidence of an acute illness and the variation in
values of IL-8 is reasoned to reflect the normal range in
children. Enzyme immunoassay showed that median levels
of IL-8 were significantly higher in the plasma of CF
patients (20 pg ml71, range 5181–586, n24) than in the
plasma of normal subjects (183 pg ml71, range 5181–
241, n25; P002) [Fig. 2(a)]. IL-8 concentrations were
not significantly dierent between the atopic CF and non-
atopic CF subgroups. Median levels of GROa in the
plasma of CF patients (33 pg ml71, range 55–198, n24)
were not significantly dierent from those in normal
subjects (34 pg ml71, range 55–64, n25; P405), and
there were also no significant dierence in plasma GROa
levels between the atopic CF and non-atopic CF subgroups
[Fig. 2(b)]. Where paired samples were available from CF
subjects IL-8 concentrations in plasma showed a correla-
tion with those in sputum (r2035, P001). There was no
correlation between plasma IL-8 (or GROa) levels and lung
function.FIG. 2. Plasma levels of (a) IL-8 and (b) GROa in atopic (A) and
Median values are shown as horizontal bars. In the CF group a
controls (P002), but GROa levels were not significantly dier
atopic and non-atopic CF subgroups in plasma levels of IL-8 oDiscussion
Characterization of the profile of factors that induce
neutrophil influx and activation in the CF lung may lead
to novel specific anti-inflammatory therapies. Growth-
related protein a (GROa) is a highly potent member of
the a sub-family of neutrophil chemokines, and is
implicated in neutrophilic inflammation in other lung
diseases (6) and in psoriasis and rheumatoid arthritis
(4,5). This study is the first to examine whether GROa
may also contribute to the intense neutrophilia that leads to
chronic lung damage in cystic fibrosis. The study confirmed
the findings of previous studies (1,2) that two other
neutrophil chemotaxins (IL-8 and LTB4) are present in
CF sputum at biologically-significant concentrations. It
also confirmed elevated levels of IL-8 in the plasma of CF
patients compared to normal subjects. However, specific
enzyme immunoassays failed to detect GROa in 21 out of
25 CF sputum samples, and GROa was present only at low
levels in the remaining four patients. Furthermore, GROa
levels were not dierent in plasma from CF and normal
subjects. The results suggest that GROa does not con-
tribute to neutrophil infiltration or activation in the CF
lung.non-atopic (NA) cystic fibrosis (CF) subjects and controls.
s a whole, IL-8 levels were significantly higher than in
ent from controls. There were no dierences between the
r GROa.
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sputum is likely to reflect a true deficiency due to impaired
local production, and not a failure of detection: firstly,
group sizes of 24–25 subjects provided a high level of
statistical power to discriminate putative dierences in
plasma GROa levels, and to detect GROa in sputum in a
small proportion of CF patients. Secondly, the sensitivity of
the enzyme immunoassay is sucient to detect GROa at
concentrations one to three orders of magnitude lower than
those at which it exerts its biological eects on neutrophils
and other cells (3). Thirdly, cytokine levels measured in CF
sputum vary widely from study to study (15), but we
investigated GROa using techniques similar to those in a
study in which significant GROa levels were detected in
BAL fluid from patients with respiratory diseases other
than CF (6). Fourthly, the structurally-related a-family
chemokine IL-8 was readily detected at nanomolar
concentrations in the same sputum samples in which GROa
levels were negligible; both IL-8 and GROa are likely to be
degraded within the airway by non-specific proteases and
there is no reason to suspect preferential degradation or
dispersal of GROa. Indeed, other studies show good
correlations between cytokine concentrations in BAL fluid
or sputum (2). Fifthly, although sputum is a notoriously
heterogeneous medium, liquefaction of sputum using the
mucolytic dithiothreitol (DTT) does not appear to aect
chemokine immunoreactivity (16,17). Sixthly, plasma levels
of GROa are likely to represent overspill of macrophage-
derived GROa from the lung and elsewhere, and GROa
was readily detected using the same methodology in the
majority of plasma samples from both CF patients and
normal controls.
Since GROa and IL-8 are produced in vitro by a similar
range of cell-types (macrophages, endothelium) following
stimulation by the same pro-inflammatory cytokines (IL-1,
TNFa), it remains unclear why high IL-8 levels were seen in
CF sputum in the absence of significant GROa. Further
work is required on the profile of stimuli in CF sputum and
their eects on IL-8 and GROa gene transcription.
However, if GROa had been present in CF sputum at
similar molar levels to those of IL-8, the greater potency of
GROa (3) would mean that GROa, not IL-8 would be the
predominant ligand at the shared IL-8 receptor on
neutrophils and other target cells. Our finding of negligible
levels of GROa in CF sputum suggests that novel anti-
inflammatory agents need only block the binding of IL-8 to
the shared receptor to reduce neutrophil migration in the
CF lung.
The second aim of the study was to investigate whether
sputum levels of neutrophil chemotaxins are dierent in
atopic and non-atopic CF patients. Our previous studies
showed that sputum cysteinyl-leukotriene (cys-LT) levels
correlate with impairment of lung function in CF (10), and
that atopic CF patients have worse lung function and
higher systemic cys-LT production (assessed by urinary
LTB4 levels) than non-atopic CF children (9,11). Since cys-
LTs and LTB4 are formed from a common substrate by the
5-lipoxygenase pathway, which appears to be upregulated
in atopy (18), and since LTB4 is found in CF sputum (1), we
hypothesized that there may be excessive LTB4 productionin the atopic CF lung which could contribute to poorer lung
function by inducing neutrophil migration, either by direct
chemotaxis, or indirectly by enhancing expression of
neutrophil chemokines such as IL-8 or GROa (12,13).
Although the atopic CF subgroup did show significantly
lower FEV1 and FVC values than their non-atopic
counterparts, our hypothesis is contradicted by the lack
of significant dierences between the subgroups in sputum
levels of LTB4, IL-8 and GROa, and in plasma levels of IL-
8 and GROa, and by the lack of correlations with lung
function. The measurements of lung function used in the
study (FEV1 and FVC) may better reflect the consequences
of over-production of the potent bronchoconstrictor cys-
LTs. The atopic CF subgroup nevertheless remain an
important subgroup who may gain additional benefit from
specific anti-inflammatory therapy in the future, particu-
larly with cys-LT receptor antagonists. Clinical trials with a
5-lipoxygenase inhibitor would help to define the contribu-
tion of LTB4 to neutrophilic inflammation in CF.
In summary, the study found no evidence that the potent
neutrophil chemokine GROa is over-produced in the CF
lung, despite confirming over-production of other neutro-
phil chemoattractants (IL-8, LTB4) that are largely derived
from similar cellular sources. Such a lack of GROa at the
site of intense neutrophil inflammatory activity may even
contribute to the inability of neutrophils in the CF lung to
eradicate respiratory infections. This finding may never-
theless promote the development of novel therapies based
upon antagonism of the restricted range of neutrophil
chemotaxins with a probable pathophysiological role in the
CF lung, especially LTB4 and/or IL-8.
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